author-photo

Kate Stumpo

Takeda Pharmaceutical Company

8

Papers

23

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)
TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

2016 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Phase 1 Dose-Escalation Study of TAK-659, an Investigational SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies

2015 Blood
Show All
- Source
- Cite
- Save
Citations (8)